Skip to Content

尊敬的客户：

目前国际形势复杂多变，关税政策尚不明朗，这可能对我们的产品价格产生一定影响。在此情况下，我们希望就订单事宜与您进行友好沟通。

基于当前的不确定性，如果您选择在此期间下单，我们将保留根据实际情况调整价格的权利。同时，我们也理解市场变化可能给您带来的困扰，因此如果在订单实际发货前因关税政策变动导致价格出现较大波动，默克将与您进行协商讨论并视情况对订单进行调整或取消。

Merck
CN
All Photos(1)

Key Documents

1446859

USP

Montelukast sodium

United States Pharmacopeia (USP) Reference Standard

Sign Into View Organizational & Contract Pricing

Select a Size

4 X 25 ML
CN¥940.97
100 ML
CN¥1,006.36
800 ML
CN¥2,710.17

CN¥940.97

Available to ship onApril 25, 2025Details

Request a Bulk Order
All Photos(1)

Select a Size

Change View
4 X 25 ML
CN¥940.97
100 ML
CN¥1,006.36
800 ML
CN¥2,710.17

About This Item

Empirical Formula (Hill Notation):
C35H35ClNO3S·Na
CAS Number:
151767-02-1
Molecular Weight:
608.17
MDL number:
MFCD00931431
UNSPSC Code:
41116107
NACRES:
NA.24

CN¥940.97

Available to ship onApril 25, 2025Details

Request a Bulk Order

grade

pharmaceutical primary standard

API family

montelukast

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

[Na+].S([C@H](CCc5c(cccc5)C(O)(C)C)c2cc(ccc2)\C=C\c3nc4c(cc3)ccc(c4)Cl)CC1(CC1)CC(=O)[O-]

InChI

1S/C35H36ClNO3S.Na/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29;/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39);/q;+1/p-1/b15-10+;/t32-;/m1./s1

InChI key

LBFBRXGCXUHRJY-HKHDRNBDSA-M

Looking for similar products? Visit Product Comparison Guide

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
52060851033555761
王氏树脂 100-200 mesh particle size, extent of labeling: 1.1 mmol/g loading

13609

王氏树脂

4-苄氧基苄醇，聚合物键合型 100-200 mesh, extent of labeling: 1.0-1.5 mmol/g OH loading, 1 % cross-linked with divinylbenzene

520608

4-苄氧基苄醇，聚合物键合型

4-苄氧基苄醇，聚合物键合型 70-90 mesh, extent of labeling: 1.5-2.0 mmol/g OH loading, 1 % cross-linked with divinylbenzene

510335

4-苄氧基苄醇，聚合物键合型

羟基甲基聚苯乙烯 200-500 mesh, extent of labeling: ~1.1 mmol/g loading

55761

羟基甲基聚苯乙烯

reaction suitability

reaction type: Fmoc solid-phase peptide synthesis

reaction suitability

reaction type: Fmoc solid-phase peptide synthesis

reaction suitability

reaction type: Fmoc solid-phase peptide synthesis

reaction suitability

reaction type: Boc solid-phase peptide synthesis, reactivity: carboxyl reactive

functional group

alcohol

functional group

alcohol

functional group

alcohol

functional group

alcohol

Quality Level

100

Quality Level

100

Quality Level

-

Quality Level

-

application(s)

peptide synthesis

application(s)

-

application(s)

-

application(s)

-

form

solid

form

-

form

-

form

solid

extent of labeling

1.1 mmol/g loading

extent of labeling

1.0-1.5 mmol/g OH loading

extent of labeling

1.5-2.0 mmol/g OH loading

extent of labeling

~1.1 mmol/g loading

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Montelukast sodium USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Y0001433

Montelukast racemate, European Pharmacopoeia (EP) Reference Standard

Y0001435

Montelukast for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0001436

Montelukast dicyclohexylamine, European Pharmacopoeia (EP) Reference Standard

Y0001434

Montelukast sodium, European Pharmacopoeia (EP) Reference Standard

1446848

Montelukast racemate, United States Pharmacopeia (USP) Reference Standard

1446815

Montelukast dicyclohexylamine, United States Pharmacopeia (USP) Reference Standard

1446837

Montelukast for peak identification, United States Pharmacopeia (USP) Reference Standard

BP1147

Montelukast dicyclohexylamine, British Pharmacopoeia (BP) Reference Standard

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

  • Specification Sheet

    • Choose from one of the most recent versions:

    Certificates of Analysis (COA)

    Lot/Batch Number

    It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

    If you need assistance, please contact Customer Support.

    Already Own This Product?

    Find documentation for the products that you have recently purchased in the Document Library.

    Visit the Document Library

    Sheng-Hua Wu et al.
    Pediatrics international : official journal of the Japan Pediatric Society, 56(3), 315-322 (2013-12-05)
    Previous studies suggested that leukotrienes (LT) were involved in the pathogenesis of Henoch-Schönlein purpura (HSP). This study investigated the efficacy of an add-on therapy with montelukast in the treatment of HSP. In this four-center, double-blind, placebo-controlled, parallel paired comparative study
    Yuki Ogawa et al.
    European journal of pediatrics, 174(4), 509-518 (2014-09-25)
    This study aimed to determine the population pharmacokinetics of doxapram in low-birth-weight (LBW) infants. A total of 92 serum concentration measurements that were obtained from 34 Japanese neonates were analyzed using nonlinear mixed-effect modeling (NONMEM). Estimates generated by NONMEM indicated
    Om Prakash Ranjan et al.
    Drug delivery, 21(7), 509-518 (2013-11-13)
    The purpose of present study was to design, optimize and evaluate osmotically controlled pulsatile release capsule (PRC) of montelukast sodium (MKS) for the prevention of episodic attack of asthma in early morning and associated allergic rhinitis. Assembly of the capsular
    Tarek A Ahmed et al.
    AAPS PharmSciTech, 15(3), 772-780 (2014-03-22)
    The objective of this study was to investigate the sustained release of a hydrophilic drug, montelukast (MK), from two biodegradable polymeric drug delivery systems, in situ implant (ISI) and in situ microparticles (ISM). N-Methyl pyrrolidone (NMP), dimethyl sulfoxide (DMSO), triacetin

    Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

    Contact Technical Service